Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
ASEP Medical reports quarterly loss of CAD 0.08 per share on CAD 0.1 million revenue
ASEP Medical released results for the quarter ended June 30, 2025. Loss per share was CAD 0.08 (prior year: -0.100 CAD). Revenue amounted to CAD 0.1 million, unchanged from the prior year. » More on finanzen.net
Financials
| (EUR) | Mar 2026 | |
|---|---|---|
| Revenue | 45.59K | - |
| Gross profit | -22.1K | - |
| Net profit | -170.27K | - |
| EBITDA | -156.99K | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €102.17K |
Number of shares | 10.86M |
52-week high/low | €0.33 - €0.0094 |
| Dividends | No |
Beta | -1.84 |
P/E ratio | -0.79 |
PEG ratio | -0.01 |
P/B ratio | 1.35 |
P/S ratio | 10.34 |
Company profile
Asep Medical Holdings Inc. konzentriert sich über seine Tochtergesellschaft ASEP Medical Inc. auf die Entwicklung eines Frühdiagnoseinstruments für Sepsis und peptidische therapeutische Behandlungen für verschiedene Anwendungen. Das Unternehmen war früher als Trenchant Life Sciences Investment Corp. bekannt und änderte seinen Namen in Asep Medical Holdings Inc. Asep Medical Holdings Inc. wurde im Jahr 2020 gegründet und hat seinen Hauptsitz in Vancouver, Kanada.
| Name | ASEP Medical Holdings |
| CEO | Richard Heinzl |
| Headquarters | Victoria,
bc Canada |
| Website | |
| Industry | Health Care Equipment & Supplies |
| IPO | 11/22/2021 |
| Employees | 6 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Cnq | ASEP.CN |
Frankfurt | JJ8.F |
Hamburg | JJ8.HM |
Düsseldorf | JJ8.DU |
München | JJ8.MU |
Pnk | SEPSF |
Discover assets
Shareholders of ASEP Medical Holdings also invest in the following assets
